NCT02052128View on ClinicalTrials.gov

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

April 30, 2016

Conditions
Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Interventions
DRUG

onapristone

Trial Locations (3)

59020

RECRUITING

Centre Oscar Lambret, Lille

75005

RECRUITING

Institut Curie Oncologie Medicale, Paris

Unknown

RECRUITING

Institut Gustave Roussy, Villejuif

Sponsors

Lead Sponsor

Arno Therapeutics
All Listed Sponsors
lead

Arno Therapeutics

INDUSTRY

NCT02052128 - Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers | Biotech Hunter | Biotech Hunter